{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:59:13Z","timestamp":1792897153605,"version":"4.5.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170905, 81801550, 81630038, 81971433"],"award-info":[{"award-number":["32170905, 81801550, 81630038, 81971433"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence of approximately 2% in the general population worldwide. Psoriasis can be triggered by infections, physical injury and certain drugs. The most common type of psoriasis is psoriasis vulgaris, which primarily features dry, well-demarcated, raised red lesions with adherent silvery scales on the skin and joints. Over the past few decades, scientific research has helped us reveal that innate and adaptive immune cells contribute to the chronic inflammatory pathological process of psoriasis. In particular, dysfunctional helper T cells (Th1, Th17, Th22, and Treg cells) are indispensable factors in psoriasis development. When stimulated by certain triggers, antigen-presenting cells (APCs) can release pro-inflammatory factors (IL-23, IFN-\u03b1 and IL-12), which further activate naive T cells and polarize them into distinct helper T cell subsets that produce numerous cytokines, such as TNF, IFN-\u03b3, IL-17 and IL-22, which act on keratinocytes to amplify psoriatic inflammation. In this review, we describe the function of helper T cells in psoriasis and summarize currently targeted anti-psoriatic therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2021.788940","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T01:10:40Z","timestamp":1639530640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":203,"title":["The Role of Helper T Cells in Psoriasis"],"prefix":"10.3389","volume":"12","author":[{"given":"Peng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhi","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of Psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61128-3","article-title":"Pathogenesis and Clinical Features of Psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.010","article-title":"Tonsillitis and Pediatric Psoriasis: Cohort and Cross-Sectional Analyses of Offspring From the Danish National Birth Cohort","volume":"82","author":"Groot","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13646","article-title":"Tattooing and Psoriasis: A Case Series and Review of the Literature","volume":"56","author":"Kluger","year":"2017","journal-title":"Int J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e8964","DOI":"10.7759\/cureus.8964","article-title":"Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level","volume":"12","author":"Awad","year":"2020","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/ptt.S126727","article-title":"Drug-Induced Psoriasis: Clinical Perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckland NZ)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e12945","DOI":"10.1111\/sji.12945","article-title":"Current Knowledge on Autoantigens and Autoantibodies in Psoriasis","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06168.x","article-title":"Perforin Expression Is Upregulated in the Epidermis of Psoriatic Lesions","volume":"151","author":"Kastelan","year":"2004","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535243","article-title":"CD56brightCD16(-) NK Cells Accumulate in Psoriatic Skin in Response to CXCL10 and CCL5 and Exacerbate Skin Inflammation","volume":"36","author":"Ottaviani","year":"2006","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast Cells and Neutrophils Release IL-17 Through Extracellular Trap Formation in Psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-Producing Gammadelta T Cells Selectively Expand in Response to Pathogen Products and Environmental Signals","volume":"31","author":"Martin","year":"2009","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8535-x","article-title":"The Inflammatory Response in Psoriasis: A Comprehensive Review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The Antimicrobial Peptide LL37 Is a T-Cell Autoantigen in Psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte Antigen Triggers Autoimmunity in Human Psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01390","article-title":"Is Psoriasis Induced by Streptococcal Superantigens and Maintained by M-Protein-Specific T Cells That Cross-React With Keratin","author":"Valdimarsson","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.01013.x","article-title":"Is an Epitope on Keratin 17 a Major Target for Autoreactive T Lymphocytes in Psoriasis","volume":"117","author":"Gudmundsdottir","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2249.2004.00600.x","article-title":"Peripheral Blood T Cell Responses to Keratin Peptides That Share Sequences With Streptococcal M Proteins Are Largely Restricted to Skin-Homing CD8(+) T Cells","volume":"138","author":"Johnston","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2009.07.008","article-title":"Psoriasis\u2013as an Autoimmune Disease Caused by Molecular Mimicry","volume":"30","author":"Valdimarsson","year":"2009","journal-title":"Trends Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1038\/s41598-018-24491-z","article-title":"Psoriasis Patients Demonstrate HLA-Cw*06:02 Allele Dosage-Dependent T Cell Proliferation When Treated With Hair Follicle-Derived Keratin 17 Protein","volume":"8","author":"Yunusbaeva","year":"2018","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJM197909063011016","article-title":"Cyclosporin A for Psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240315","article-title":"T-Cell Clones From Psoriasis Skin-Lesions Can Promote Keratinocyte Proliferation In-Vitro via Secreted Products","volume":"24","author":"Prinz","year":"1994","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-407-00338-5.50047-8","article-title":"Epidermal Lymphocytes-T and Hla-Dr Expression in Psoriasis","volume":"110","author":"Baker","year":"1984","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T-Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized Anti-IFN-Gamma (HuZAF) in the Treatment of Psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-Producing CD4+ Effector T Cells Develop via a Lineage Distinct From the T Helper Type 1 and 2 Lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and Safety Results From a Phase III, Randomized Controlled Trial Comparing the Safety and Efficacy of Briakinumab With Etanercept and Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results From Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet (London England)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5","article-title":"Tildrakizumab Versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and reSURFACE 2): Results From Two Randomised Controlled, Phase 3 Trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet (London England)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients With Psoriasis: 76-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet (London England)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497","article-title":"Development, Cytokine Profile and Function of Human Interleukin 17-Producing Helper T Cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual Neutralization of Both Interleukin 17A and Interleukin 17F With Bimekizumab in Patients With Psoriasis: Results From BE ABLE 1, a 12-Week Randomized, Double-Blinded, Placebo-Controlled Phase 2b Trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493","article-title":"A Prospective Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Brodalumab in Patients With Moderate-to-Severe Plaque Psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2013Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 Cytokine, Mediates IL-23-Induced Dermal Inflammation and Acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08769.x","article-title":"Th17 Cytokines Interleukin (IL)-17 and IL-22 Modulate Distinct Inflammatory and Keratinocyte-Response Pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01323","article-title":"The Interleukin-23\/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis","volume":"9","author":"Schon","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-Producing \"T22\" T Cells Account for Upregulated IL-22 in Atopic Dermatitis Despite Reduced IL-17-Producing T(H)17 T Cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/ni.1770","article-title":"Identification of a Human Helper T Cell Population That has Abundant Production of Interleukin 22 and Is Distinct From T-H-17, T(H)1 and T(H)2 Cells","volume":"10","author":"Trifari","year":"2009","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17(+) T Cell Trafficking and Development by IFN-Gamma: Mechanism and Pathological Relevance in Psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T Cells and Immune Tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","article-title":"Role of Regulatory T Cells in Psoriasis Pathogenesis and Treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/09674845.2016.1207869","article-title":"Immunophenotyping of T Cells in the Peripheral Circulation in Psoriasis","volume":"73","author":"Priyadarssini","year":"2016","journal-title":"Br J Biomed Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2011.1362","article-title":"CD4+ CD25+ T-Regulatory Cells in Psoriasis. Correlation Between Their Numbers and Biologics-Induced Clinical Improvement","volume":"21","author":"Richetta","year":"2011","journal-title":"Eur J Dermatol EJD"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 Cells are Accompanied by FoxP3(+) Treg Cell Accumulation and Correlated With Psoriasis Disease Severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2133.2010.09742.x","article-title":"Foxp3+ Regulatory T Cells and Related Cytokines Differentially Expressed in Plaque vs. Guttate Psoriasis Vulgaris","volume":"163","author":"Yan","year":"2010","journal-title":"Br J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08504.x","article-title":"Profiles of Foxp3+ Regulatory T Cells in Eczematous Dermatitis, Psoriasis Vulgaris and Mycosis Fungoides","volume":"158","author":"Fujimura","year":"2008","journal-title":"Br J Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000093849","article-title":"Identification of Lesional CD4+ CD25+ Foxp3+ Regulatory T Cells in Psoriasis","volume":"213","author":"Bovenschen","year":"2006","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.035","article-title":"Dysregulation of Akt-FOXO1 Pathway Leads to Dysfunction of Regulatory T Cells in Patients With Psoriasis","volume":"139","author":"Li","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12404","article-title":"Characterization of Th17 and FoxP3(+) Treg Cells in Paediatric Psoriasis Patients","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001455","article-title":"Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression","volume":"186","author":"Goodman","year":"2011","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.06.055","article-title":"MiR-200a Expression in CD4+ T Cells Correlates With the Expression of Th17\/Treg Cells and Relevant Cytokines in Psoriasis Vulgaris: A Case Control Study","volume":"93","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci34916","article-title":"TGF-Beta-Dependent Suppressive Function of Tregs Requires Wild-Type Levels of CD18 in a Mouse Model of Psoriasis","volume":"118","author":"Wang","year":"2008","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391","article-title":"IL-6: Regulator of Treg\/Th17 Balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate Into IL-17A-Producing Cells and Are Found in Lesional Skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202399","article-title":"Reduced CD18 Levels Drive Regulatory T Cell Conversion Into Th17 Cells in the CD18hypo Pl\/J Mouse Model of Psoriasis","volume":"190","author":"Singh","year":"2013","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3069521","article-title":"Notch1 Signaling Regulates the Th17\/Treg Immune Imbalance in Patients With Psoriasis Vulgaris","volume":"2018","author":"Ma","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2019.01.013","article-title":"Clinical Significance and Immunobiology of IL-21 in Autoimmunity","volume":"99","author":"Long","year":"2019","journal-title":"J Autoimmun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13027","article-title":"Increased Circulating Follicular Helper T Cells and Activated B Cells Correlate With Disease Severity in Patients With Psoriasis","volume":"29","author":"Niu","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7346030","article-title":"Activated Circulating T Follicular Helper Cells Are Associated With Disease Severity in Patients With Psoriasis","volume":"2016","author":"Wang","year":"2016","journal-title":"J Immunol Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1995","article-title":"Involvement of Interleukin-21 in the Epidermal Hyperplasia of Psoriasis","volume":"15","author":"Caruso","year":"2009","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2016.09.008","article-title":"Altered Circulating T Follicular Helper Cell Subsets in Patients With Psoriasis Vulgaris","volume":"181","author":"Wang","year":"2017","journal-title":"Immunol Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.15","article-title":"New Insights of T Cells in the Pathogenesis of Psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A Global Phase III Randomized Controlled Trial of Etanercept in Psoriasis: Safety, Efficacy, and Effect of Dose Reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)67566-6","article-title":"Infliximab Induction and Maintenance Therapy for Moderate-to-Severe Psoriasis: A Phase III, Multicentre, Double-Blind Trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet (London England)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and Safety of Infliximab vs. Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis: Results of an Open-Label, Active-Controlled, Randomized Trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks From 2 Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blind, Etanercept- and Placebo-Controlled Study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients With Psoriasis: 52-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet (London England)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and Safety of Briakinumab vs. Etanercept and Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"Br J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Continuous Treatment of Patients With Moderate to Severe Psoriasis: Results From the Phase III, Double-Blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31773-8","article-title":"Guselkumab Versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results From a Phase 3, Randomised Controlled Trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet (London England)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18696","article-title":"Guselkumab Is Superior to Fumaric Acid Esters in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment: Results From a Randomized, Active-Comparator-Controlled Phase IIIb Trial (POLARIS)","volume":"183","author":"Tha\u00e7i","year":"2020","journal-title":"Br J Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30952-3","article-title":"Risankizumab Compared With Adalimumab in Patients With Moderate-to-Severe Plaque Psoriasis (IMMvent): A Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet (London England)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and Safety of Risankizumab vs. Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis (IMMerge): Results From a Phase III, Randomized, Open-Label, Efficacy-Assessor-Blinded Clinical Trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate to Severe Plaque Psoriasis: CLEAR, A Randomized Controlled Trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects With Moderate-to-Severe Plaque Psoriasis Up to 1 Year: Results From the CLEAR Study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab Maintains Superiority Over Ustekinumab in Clearing Skin and Improving Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: 52-Week Results From a Double-Blind Phase 3b Trial (CLARITY)","volume":"35","author":"Bagel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of Ixekizumab With Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results From Two Phase 3 Randomised Trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet (London England)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-To-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through 108 Weeks of a Randomized, Controlled Phase 3 Clinical Trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab Sustains High Level of Efficacy and Favourable Safety Profile Over 4 Years in Patients With Moderate Psoriasis: Results From UNCOVER-3 Study","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18384","article-title":"A 24-Week Multicentre, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab vs. Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509","article-title":"A Head-to-Head Comparison of Ixekizumab vs. Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results From a Randomized, Double-Blinded Trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab With Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16932","article-title":"A Phase 4, Randomized, Head-to-Head Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate-to-Severe Plaque Psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet (London England)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the Treatment of Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: Results From the 24-Week Randomised, Double-Blind, Placebo-Controlled Period of the SPIRIT-P2 Phase 3 Trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet (London England)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an Interleukin-17A Specific Monoclonal Antibody, for the Treatment of Biologic-Naive Patients With Active Psoriatic Arthritis: Results From the 24-Week Randomised, Double-Blind, Placebo-Controlled and Active (Adalimumab)-Controlled Period of the Phase III Trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, in Patients With Psoriatic Arthritis (FUTURE 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet (London England)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in Patients With Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet (London England)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and Safety of Brodalumab in Patients With Psoriasis Who had Inadequate Responses to Ustekinumab: Subgroup Analysis of Two Randomized Phase III Trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br J Dermatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.007","article-title":"Brodalumab in the Treatment of Moderate to Severe Psoriasis in Patients When Previous Anti-Interleukin 17A Therapies Have Failed","volume":"81","author":"Kimmel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.712112","article-title":"Discontinued Drugs 2011: Pulmonary, Allergy, Gastrointestinal and Arthritis","volume":"21","author":"Antoniu","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory Role of the JAK STAT Kinase Signalling System on the IL-23\/IL-17 Cytokine Axis in Psoriatic Arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib Versus Etanercept or Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis: Patient-Reported Outcomes From a Phase 3 Study","volume":"30","author":"Valenzuela","year":"2016","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B108","unstructured":""},{"key":"B109","unstructured":""},{"key":"B110","unstructured":""},{"key":"B111","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 Inhibitor PF-06700841 in Patients With Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B112","unstructured":""},{"key":"B113","unstructured":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.788940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T01:10:45Z","timestamp":1639530645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.788940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2021.788940"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.788940","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"788940"}}